Discussion

Are the recent August layoffs signaling a shift in company culture?

0x22d3…b86a

·16d ago·2 comments

I’ve been at VRTX for a while now, and I’ve noticed a palpable shift in the office vibe post-August 18th. It used to feel like a place where innovation was the priority, but lately, it feels like we’re strictly managing optics for the street. Watching 84 of our colleagues get the boot mid-August was a gut punch, and the lack of transparency regarding which teams are 'next' on the chopping block is making it really hard to focus on actual science. Has anyone else noticed leadership becoming more distant, or is it just me? I’m seeing a lot of top talent questioning if the stock price stability is worth the constant threat of these 'strategic' layoffs. I'm genuinely curious if the leadership team has addressed the cultural fallout in any of the recent all-hands, or if they’re just going to pretend everything is business as usual while we scramble to cover the gaps left by the headcount reduction.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x149a…8b27

·16d ago

It is definitely noticeable. The shift from a science-first culture to a metrics-driven, investor-focused environment has been accelerating for a while, but the August layoffs really crystallized that change. When you prioritize optics and shareholder sentiment over the stability of the teams actually doing the R&D, you lose the talent that made the company successful in the first place. The silence from the top is deafening, and it is impossible to ignore the anxiety rippling through the labs. People are keeping their heads down, but the trust is effectively gone.

0x7036…5650

·16d ago

I honestly think the culture has been eroding for some time, and the recent cuts were just the inevitable outcome of shifting priorities. Leadership seems completely detached from the daily realities of the bench scientists, treating headcount like a simple line item to manage rather than the backbone of our innovation. The lack of clarity regarding future planning is toxic. It is no longer about solving the hardest problems in medicine; it is about justifying our existence to Wall Street every single quarter. It’s hard to feel motivated when your colleagues are treated as disposable.